Johnson & Johnson executive Joaquin Duato said the company wants to help save lives by fast tracking its Ebola vaccine.» Read More
The U.S. Medicare agency said Monday that, unless it receives new evidence, it will not reverse a decision to cut payments for certain uses of anemia drugs, including Amgen's Aranesp.
After being down about half-a-dollar in early trading, volatile shares of Amgen are trimming their loses and heading back into positive territory at this writing. That turnaround could be from the dissemination of a research note from Wachovia biotech analyst George Farmer.
Millennium Pharmaceuticals said on Tuesday initial results from a large trial of its cancer drug Velcade as an initial treatment for multiple myeloma were so good that the trial was stopped early to allow patients in the control group to receive the therapy.
Could a new pharmaceutical partnership be the best way to trade the rise in diabetes? In Thursday’s Web.Extra the traders reveal how to play the latest news. Also get their trades on hard drive behemoths Western Digital and Seagate.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
In Wednesday’s Sea Change, Pete Najarian brings you a trade so good it will leave you weak in the knees.
Recently I blogged about the hiring of a new CEO at ImClone Systems and the unique clause in his contract requiring him to buy half-a-million dollars worth of stock in the company. My suspicion was that ImClone Chairman and billionaire shareholder Carl Icahn had a hand in that.
As far as he's concerned, there are plenty of reasons to own this medical diagnostics company.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
A panel of advisers to U.S. health regulators voted on Tuesday to reject new restrictions on anemia drugs, a win for drugmakers Amgen and Johnson & Johnson .
Is the Senate coming to the rescue of patients, investors or both? That's the question being raised after the passage of a non-binding resolution telling Medicare to "immediately reconsider" its new policy to cut anemia drug use and reimbursement. Analysts are stunned by the move.
So, I thought I'd be spending today monitoring the webcast of the FDA Advisory Committees that are meeting to decide whether doctors should use less of the anemia drugs from Amgen and Johnson & Johnson to treat kidney dialysis patients.
Wall Street is counting down to next week's Fed meeting and not much else is influencing trading. Stocks are readying for a higher opening as investors wait for a speech from Fed Chairman Ben Bernanke later this morning and watch the action at OPEC.
Patients given drug-coated stents after an acute heart attack are nearly five times more likely to die six months to two years later than those with bare metal forms of the arterial scaffolding, research showed on Tuesday.
A U.S. court dismissed some claims in a lawsuit filed by Johnson & Johnson over its failed bid for Guidant.
There are two kinds of companies in the market – cyclical and secular. One of the most important moves in the game is to know when to shift money from one to the other.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Warren Buffett's Berkshire Hathaway has just revealed its portfolio holdings for the second quarter. New additions: Bank of America and Dow Jones, plus increased stakes in some healthcare names.
At CNBC we use -- among others -- a couple of primary business news wire services -- NewsEdge, part of Thomson, and Relegence, part of AOL.
Late Thursday, ImClone Systems announced it has finally hired a permanent CEO. It'd been without one for about two years. The biotech company which makes the cancer drug Erbitux and became reluctantly famous in the Martha Stewart stock-trading case tapped a guy named John Johnson for the role.
Johnson & Johnson, the drug/medical device/consumer health products company reeling from a plunge in sales of its anemia drug, Procrit, and its drug-coated stent, Cypher, is going to court. Not to defend a lucrative pharmaceutical patent, but to get The Red Cross to stop using its red cross logo on certain marketed products like humidifiers and grooming tools.
Johnson & Johnson, the pharmaceutical giant which uses a Red Cross as its trademark, filed a lawsuit Wednesday against the American Red Cross, demanding that the charity halt the use of the red cross symbol on products it sells to the public.